Download - De la EPOC al Cancer de Pulmón
![Page 1: De la EPOC al Cancer de Pulmón](https://reader033.vdocumento.com/reader033/viewer/2022052313/5887ab0a1a28aba2088b68ad/html5/thumbnails/1.jpg)
DE LA EPOC AL CANCER DE PULMON
Dr. J. Roig CutillasHospital N. Sra. de Meritxell Servei de PneumologiaANDORRA
I Conferencia Mediterránea sobre Derechos Humanos y TabaquismoCastelló 2009
![Page 2: De la EPOC al Cancer de Pulmón](https://reader033.vdocumento.com/reader033/viewer/2022052313/5887ab0a1a28aba2088b68ad/html5/thumbnails/2.jpg)
Concepto y prevalencia de EPOC Riesgo de cáncer de pulmón en EPOC Aumento de riesgo: sexo y raza Implicaciones en programas de screening Implicaciones de esta asociación en la
aproximación terapéutica Perspectivas de futuro
EPOC Y CANCER DE PULMON
![Page 3: De la EPOC al Cancer de Pulmón](https://reader033.vdocumento.com/reader033/viewer/2022052313/5887ab0a1a28aba2088b68ad/html5/thumbnails/3.jpg)
¿Qué es la EPOC?
La enfermedad pulmonar obstructiva crónica (EPOC) es una entidad caracterizada por una limitación del flujo aéreo de curso progresivo, poco reversible, pero prevenible y tratable. Esta limitación funcional se asocia a una respuesta inflamatoria anómala del pulmón frente a partículas nocivas o gases, en particular el humo del tabaco.
![Page 4: De la EPOC al Cancer de Pulmón](https://reader033.vdocumento.com/reader033/viewer/2022052313/5887ab0a1a28aba2088b68ad/html5/thumbnails/4.jpg)
Espirometría
![Page 5: De la EPOC al Cancer de Pulmón](https://reader033.vdocumento.com/reader033/viewer/2022052313/5887ab0a1a28aba2088b68ad/html5/thumbnails/5.jpg)
Prevalencia España
En España 1.300.000 personas entre 40 y 69 años padecen una EPOC. El 78% no estaba diagnosticado.
Leves: 38.3%Mod.: 39.7%Graves: 22%
Sobradillo V et al. Chest. 2000 Oct;118(4):981-9.
![Page 6: De la EPOC al Cancer de Pulmón](https://reader033.vdocumento.com/reader033/viewer/2022052313/5887ab0a1a28aba2088b68ad/html5/thumbnails/6.jpg)
Enf cardiaca isquémica Enf cerebrovascularInfección respiratoriaEnf diarreicasTrast perinatalesEPOCEPOCTuberculosisSarampiónAccidentes de tráficoCáncer de pulmón
6ª
3ª
Cáncer gástricoSIDASuicidio
1990 2020
Murray & Lopez. Lancet 1997
Mortalidad Global Prevista
![Page 7: De la EPOC al Cancer de Pulmón](https://reader033.vdocumento.com/reader033/viewer/2022052313/5887ab0a1a28aba2088b68ad/html5/thumbnails/7.jpg)
EPOC: factor de riesgo de cáncer de pulmón
Asociación definida de forma incontrovertible Mannino DM. Arch Intern Med 2003 (FEV1 < 80%)
↑ de OR en estudios con ↓ de FEV1 < 60% Kuller LH. Am J Epidemiol 1990
Factor de riesgo independiente de tabaco Skilrud D; Tockman M. Ann Intern Med 1986, 1987 EPOC + ?: población de riesgo con posible
beneficio de screening → problemática CT Mulshine J. NEJM 2005; Mahadevia P. JAMA 2006
![Page 8: De la EPOC al Cancer de Pulmón](https://reader033.vdocumento.com/reader033/viewer/2022052313/5887ab0a1a28aba2088b68ad/html5/thumbnails/8.jpg)
Tockman MS. Airways obstruction and the risk for lung cancer. Ann Intern Med 1987
![Page 9: De la EPOC al Cancer de Pulmón](https://reader033.vdocumento.com/reader033/viewer/2022052313/5887ab0a1a28aba2088b68ad/html5/thumbnails/9.jpg)
Rabe K. N Engl J Med 2007;356:851-854
Causes of Death in Patients with COPD. TORCH study 2007
![Page 10: De la EPOC al Cancer de Pulmón](https://reader033.vdocumento.com/reader033/viewer/2022052313/5887ab0a1a28aba2088b68ad/html5/thumbnails/10.jpg)
Sin DD. Mortality in COPD: role of comorbidities. Eur Respir J 2006
![Page 11: De la EPOC al Cancer de Pulmón](https://reader033.vdocumento.com/reader033/viewer/2022052313/5887ab0a1a28aba2088b68ad/html5/thumbnails/11.jpg)
RELATION OF LUNG CANCER MORTALITY TO COPD AMONG NEVER SMOKERS IN THE CANCER PREVENTION STUDY II COHORT, 1982–2002
Previous Lung Disease No. of Lung Cancer Deaths
Person-Years
Death Rate*
Fully Adjusted Hazard Ratio
(95% CI) Chronic bronchitis
Yes 48 210,569 19.0 0.96 (0.72, 1.28)
No 1,711 7,932,210 21.1 1.00
Emphysema Yes 20 35,418 42.0 1.66 (1.06, 2.59)
No 1,739 8,107,361 21.0 1.00
Chronic bronchitis and emphysema
Yes 8 10,585 52.6 2.44 (1.22, 4.90)
No 1,751 7,907,377 21.1 1.00
Turner MC. COPD is associated with lung cancer mortality in a prospective study of never smokers. AJRCCM 2007
![Page 12: De la EPOC al Cancer de Pulmón](https://reader033.vdocumento.com/reader033/viewer/2022052313/5887ab0a1a28aba2088b68ad/html5/thumbnails/12.jpg)
![Page 13: De la EPOC al Cancer de Pulmón](https://reader033.vdocumento.com/reader033/viewer/2022052313/5887ab0a1a28aba2088b68ad/html5/thumbnails/13.jpg)
![Page 14: De la EPOC al Cancer de Pulmón](https://reader033.vdocumento.com/reader033/viewer/2022052313/5887ab0a1a28aba2088b68ad/html5/thumbnails/14.jpg)
Autofluorescence bronchoscopy: detection of early epithelial abnormalities
![Page 15: De la EPOC al Cancer de Pulmón](https://reader033.vdocumento.com/reader033/viewer/2022052313/5887ab0a1a28aba2088b68ad/html5/thumbnails/15.jpg)
Frequency distribution of FEV1 (%) predicted in smoking controls ( ) and lung cancer cases ( ) (n = 602) matched for age, sex and smoking history.
Young RP et al. COPD prevalence is increased in lung cancer, independent of age, sex and smoking history. Eur Respir J 2009; 34:380-386
![Page 16: De la EPOC al Cancer de Pulmón](https://reader033.vdocumento.com/reader033/viewer/2022052313/5887ab0a1a28aba2088b68ad/html5/thumbnails/16.jpg)
Screening: otros factores asociados a riesgo alto de cáncer de pulmón en EPOC
↑ riesgo por otros carcinógenos: Ar, asbesto Chen C. JAMA 2004; Smith K. Clin Chest Med 2002
↑ de riesgo por factores raciales-étnicos Haiman C, NEJM 2006; Coté M. JAMA 2005
Son las mujeres más susceptibles? Rivera MP. Clin Ch Med 2004; Patel J. JAMA 2006 ↑ de riesgo por factores genéticos (familiar) Schwartz AG. Familial lung cancer: genetic
susceptibility and relationships to COPD. Am J Respir Crit Care 2006 (cromosomas 6q, 12)
![Page 17: De la EPOC al Cancer de Pulmón](https://reader033.vdocumento.com/reader033/viewer/2022052313/5887ab0a1a28aba2088b68ad/html5/thumbnails/17.jpg)
Coté M. Risk of lung cancer among white and black relatives of individuals with early –onset lung cancer. JAMA 2005 Early onset LC: diagnóstico edad < 45 años Mayor riesgo en parientes fumadores con historia
familiar en primer grado Familiares de 1er grado de raza negra mayor riesgo
que en raza blanca (OR 2.07) Asociación de EPOC con “early-onset lung cancer”
identificada en familiares blancos (OR 1.48) pero no en los de raza negra después de ajuste para otras variables
![Page 18: De la EPOC al Cancer de Pulmón](https://reader033.vdocumento.com/reader033/viewer/2022052313/5887ab0a1a28aba2088b68ad/html5/thumbnails/18.jpg)
Predicted Rates of Lung Cancer among Men Who Currently Smoke 10 Cigarettes per Day (Panel A) or 30 Cigarettes per Day (Panel B) and among Women Who Currently Smoke 10
Cigarettes per Day (Panel C) or 30 Cigarettes per Day (Panel D)
Haiman, C. et al. N Engl J Med 2006;354:333-342
Haiman CA. Ethnic and racial differences in the smoking-related risk of lung cancer. NEJM 2006
![Page 19: De la EPOC al Cancer de Pulmón](https://reader033.vdocumento.com/reader033/viewer/2022052313/5887ab0a1a28aba2088b68ad/html5/thumbnails/19.jpg)
FEMALES
Jemal A. Cancer Statistics. CA Cancer J Clin 2003
![Page 20: De la EPOC al Cancer de Pulmón](https://reader033.vdocumento.com/reader033/viewer/2022052313/5887ab0a1a28aba2088b68ad/html5/thumbnails/20.jpg)
Wasswa-Kintu S. Relationship between reduced FEV1 and the risk of lung cancer: systematic review and meta-analysis. Thorax 2005
![Page 21: De la EPOC al Cancer de Pulmón](https://reader033.vdocumento.com/reader033/viewer/2022052313/5887ab0a1a28aba2088b68ad/html5/thumbnails/21.jpg)
Ben-Zaken Cohen S. The growing burden of COPD and lung cancer in women. Examining sex differences in cigarette smoke metabolism. AJRCCM 2007
Sobreexpresión de enzimas CYP por estrógenos
Mayor frecuencia de mutaciones p53 Mayor depósito de partículas por:
Vías aéreas más pequeñasAumento de reactividad bronquial
Menor capacidad de reparación de DNA
![Page 23: De la EPOC al Cancer de Pulmón](https://reader033.vdocumento.com/reader033/viewer/2022052313/5887ab0a1a28aba2088b68ad/html5/thumbnails/23.jpg)
Autofluorescence bronchoscopy: detection of early epithelial abnormalities
![Page 24: De la EPOC al Cancer de Pulmón](https://reader033.vdocumento.com/reader033/viewer/2022052313/5887ab0a1a28aba2088b68ad/html5/thumbnails/24.jpg)
The relationship between progression of lesion and various baseline factors
Variables Odds ratio C-statistic p valueCRP,mg/l 2.59 0.64 0.014Pack-years 2.34 0.62 0.009FEV1,% predicted 0.40 0.69 0.005
Current smoker 2.94 0.57 0.218Age 1.00 0.64 0.990Men 1.22 0.56 0.812
Sin DD. Progression of airway dysplasia and C-reactive protein in smokers at high risk of lung cancer. Am J Respir Crit Care Med 2005
![Page 25: De la EPOC al Cancer de Pulmón](https://reader033.vdocumento.com/reader033/viewer/2022052313/5887ab0a1a28aba2088b68ad/html5/thumbnails/25.jpg)
Parimon T. Inhaled corticosteroids and risk of lung cancer among patients with COPD. AJRCCM 2007
![Page 26: De la EPOC al Cancer de Pulmón](https://reader033.vdocumento.com/reader033/viewer/2022052313/5887ab0a1a28aba2088b68ad/html5/thumbnails/26.jpg)
Spira A. Multidisciplinary management of lung cancer. NEJM 2004
Sequencial pathogenic changes involved in lung cancer
![Page 27: De la EPOC al Cancer de Pulmón](https://reader033.vdocumento.com/reader033/viewer/2022052313/5887ab0a1a28aba2088b68ad/html5/thumbnails/27.jpg)
El inicio de la quimioterapia (1946), basado en la investigación de la guerra química
Cl Cl
N
Aminopterin (1948)
Farber S, et al. N Engl J Med 1948
H2N
N
N N
N
HN
HN
O
OH
OHO
NH2
O
Goodman L, et al. JAMA 1946
Mustine (1946)
1940 1950 1960 1970 1980 1990 2000 20101930
![Page 28: De la EPOC al Cancer de Pulmón](https://reader033.vdocumento.com/reader033/viewer/2022052313/5887ab0a1a28aba2088b68ad/html5/thumbnails/28.jpg)
1940 1950 1960 1970 1980 1990 2000 20101930
Nuevos agentes citotóxicos
The first platinum: discovery of cisplatin
NH3NH3
Pt
Cl Cl
The first taxane:discovery of paclitaxel in bark of the Pacific yew
1965 1967
![Page 29: De la EPOC al Cancer de Pulmón](https://reader033.vdocumento.com/reader033/viewer/2022052313/5887ab0a1a28aba2088b68ad/html5/thumbnails/29.jpg)
Herbst R and Lippman S. N Engl J Med 2007;356:76-78
Herbst RS. Molecular Signatures of Lung Cancer — Toward Personalized Therapy. NEJM 2007
![Page 30: De la EPOC al Cancer de Pulmón](https://reader033.vdocumento.com/reader033/viewer/2022052313/5887ab0a1a28aba2088b68ad/html5/thumbnails/30.jpg)
![Page 31: De la EPOC al Cancer de Pulmón](https://reader033.vdocumento.com/reader033/viewer/2022052313/5887ab0a1a28aba2088b68ad/html5/thumbnails/31.jpg)
EPOC ↔ CáncerConsideraciones sobre quimioterapia
Aumento del riesgo de toxicidad pulmonar para diversos agentes como mitomicina
Derrame pleural en síndrome de “fluid retention” (trasudado) con docetaxel
Depresión respiratoria con ifosfamida y metotrexate en EPOC severa-Sleep apnea
Neuropatia (vincristina) puede afectar la función muscular respiratoria
Aldrich T, Clin Chest Med 1990; Klein D, Can Anaesth Soc J 1983; Roig J, Clin Pulm Med 2006
![Page 32: De la EPOC al Cancer de Pulmón](https://reader033.vdocumento.com/reader033/viewer/2022052313/5887ab0a1a28aba2088b68ad/html5/thumbnails/32.jpg)
![Page 33: De la EPOC al Cancer de Pulmón](https://reader033.vdocumento.com/reader033/viewer/2022052313/5887ab0a1a28aba2088b68ad/html5/thumbnails/33.jpg)
First pneumonectomy performed in a lung cancer patient: 1933 !!
1940 1950 1960 1970 1980 1990 2000 2010
Graham E, et al. JAMA 1933
1930
![Page 34: De la EPOC al Cancer de Pulmón](https://reader033.vdocumento.com/reader033/viewer/2022052313/5887ab0a1a28aba2088b68ad/html5/thumbnails/34.jpg)
EPOC ↔ CáncerAlgunas consideraciones quirúrgicas
Función pulmonar y límite de resecabilidadRoig J. SEPAR - FMC 2006 Valor de resección limitada (>70 años)Mery C. Chest 2005 VATS?Muraoka M. Jpn J Thorac Cardiovasc Surg 2006 Esternotomía media?Asaph J. Am J Surg 1984; Miyamoto H. ANZ J Surg 2005 Dolor post-cirugía aumenta riesgo de infecciónBelda J. Chest 2005; Clin Pulm Med 2006
![Page 35: De la EPOC al Cancer de Pulmón](https://reader033.vdocumento.com/reader033/viewer/2022052313/5887ab0a1a28aba2088b68ad/html5/thumbnails/35.jpg)
Journal of Thoracic Oncology: Volume 1(9)November 2006pp 960-964
Wedge Resection for Non-small Cell Lung Cancer in Patients with Pulmonary Insufficiency: Prospective
Ten-Year Survival
Griffin, John P. MD*; Eastridge, Charles E. MD†‡; Tolley, Elizabeth A. PhD§; Pate, James W. MD||
Divisions of *Pulmonary and Critical Care Medicine, §Preventive Medicine and Medicine Division of Biostatistics and Epidemiology,
and ||Department of Surgery, University of Tennessee Health Science Center, Memphis, TN; and ‡Thoracic Surgery Section
Surgery Service, VA Medical Center, Memphis, TN.
![Page 36: De la EPOC al Cancer de Pulmón](https://reader033.vdocumento.com/reader033/viewer/2022052313/5887ab0a1a28aba2088b68ad/html5/thumbnails/36.jpg)
FIGURE 1. Kaplan-Meier plot for a consecutive surgically resected series of patients with non-small cell lung cancer from 1988 to 1992 at Memphis VA Medical Center, based on all-cause mortality.Griffin JP. Wedge resection for NSCLC in patients with pulmonary insufficiency. J Thor Oncol 2006
![Page 37: De la EPOC al Cancer de Pulmón](https://reader033.vdocumento.com/reader033/viewer/2022052313/5887ab0a1a28aba2088b68ad/html5/thumbnails/37.jpg)
Sekine I. Association of COPD and tumor recurrence in patients with stage IA lung cancer after complete resection. Ann Thorac Surg 2007
n = 442 Estadio I: lobectomía 362 COPD (FEV1/FVC <70%) Aumento neumonía y traqueostomía COPD No dif. en otras complicaciones postcirugía Supervivencia global peor en COPD
(p<0.001) COPD asociado con recurrencia (p=0.0105)
![Page 38: De la EPOC al Cancer de Pulmón](https://reader033.vdocumento.com/reader033/viewer/2022052313/5887ab0a1a28aba2088b68ad/html5/thumbnails/38.jpg)
A-alveolo normal B-enfisema C-bronquiolo y alveolo normales D-enfisema
![Page 39: De la EPOC al Cancer de Pulmón](https://reader033.vdocumento.com/reader033/viewer/2022052313/5887ab0a1a28aba2088b68ad/html5/thumbnails/39.jpg)
Ueda K. Computed tomography- diagnosed emphysema, not airway obstruction, is associated with the prognostic outcome of early-stage lung cancer. Clin Cancer Res 2006
![Page 40: De la EPOC al Cancer de Pulmón](https://reader033.vdocumento.com/reader033/viewer/2022052313/5887ab0a1a28aba2088b68ad/html5/thumbnails/40.jpg)
EPOC ↔ CáncerConsideraciones sobre radioterapia
Elevado riesgo obliga a optimizar campo a irradiarSpiro SG. Am J Respir Crit Care Med 2005 PET muy útil en atelectasias y PET- CT en la
evaluación de respuesta y predicción evolución?Manus M. J Clin Oncol 2003; Gamez C. J Thor Oncol 2006 Efecto protector de amifostina en ser humano Modelo animal: vitamina A, pentoxifilina, IECA,
Mn superoxide dismutasa gene therapyAbratt RP. Clin Chest Med 2004
![Page 41: De la EPOC al Cancer de Pulmón](https://reader033.vdocumento.com/reader033/viewer/2022052313/5887ab0a1a28aba2088b68ad/html5/thumbnails/41.jpg)
Fusion PET- CT scan
![Page 42: De la EPOC al Cancer de Pulmón](https://reader033.vdocumento.com/reader033/viewer/2022052313/5887ab0a1a28aba2088b68ad/html5/thumbnails/42.jpg)
![Page 43: De la EPOC al Cancer de Pulmón](https://reader033.vdocumento.com/reader033/viewer/2022052313/5887ab0a1a28aba2088b68ad/html5/thumbnails/43.jpg)
Riesgo extravasación intratorácica Hipercoagulabilidad asociada a neoplasia Hipercoagulabilidad por terapia
concomitante como eritropoyetina o acetato de megestrol
TEP asociado a vias centrales y reservorios sc (Portacath)
Hemoptisis en QT intraarterial pulmonar
Domingo C & Roig J. Neglected respiratory toxicity caused by cancer therapy. Open Respir Med Review 2007
![Page 44: De la EPOC al Cancer de Pulmón](https://reader033.vdocumento.com/reader033/viewer/2022052313/5887ab0a1a28aba2088b68ad/html5/thumbnails/44.jpg)
Spitz MR et al. The CHRNA5-A3 Region on Chromosome 15q24-25.1 Is a Risk Factor Both for Nicotine Dependence and for Lung Cancer. J Natl Cancer Inst 2008;100: 1552 – 1556.
Common variants in the nicotinic acetylcholine receptor gene cluster on chromosome 15q24-25.1 were associated with lung cancer risk in three recently published independently conducted genome-wide association studies
The variants were associated with higher risks of lung cancer in lower smoking-exposed strata, and in individuals with a strong family history of lung or smoking-related cancers. In contrast, we found no evidence that the variants were associated with elevated risks in 547 lifetime never-smoking lung cancer case subjects
![Page 45: De la EPOC al Cancer de Pulmón](https://reader033.vdocumento.com/reader033/viewer/2022052313/5887ab0a1a28aba2088b68ad/html5/thumbnails/45.jpg)
Young RP et al. Lung cancer gene associated with COPD: triple whammy or possible confounding effect? Eur Respir J 2008; 32:1158-1164
Several large genome-wide association studies have identified a putative "lung cancer" locus in the nicotinic acetylcholine receptor subunit genes (nAChR) on 15q25
Comparison of genotype frequencies between three matched smoking cohorts.
The AA genotype was found to be more frequent and was seen in 437 (16%) lung cancer cases and 445 (14%) COPD cases compared with 475 (9%) healthy smoking controls
![Page 46: De la EPOC al Cancer de Pulmón](https://reader033.vdocumento.com/reader033/viewer/2022052313/5887ab0a1a28aba2088b68ad/html5/thumbnails/46.jpg)
Granville CA. Identification of a highly effective Rapamycin schedule that markedly reduces in size, multiplicity and phenotypic progression of tobacco carcinogen-induced murine lung tumors. Clin Cancer Res 2007
Inducción de tumores en el modelo animal por el carcinógeno de tabaco NNK
Administración de rapamicina (inhibidor de mTOR) en diferentes esquemas
Administración precoz diaria ↓ tamaño tumoral y multiplicidad (90%)
Aprobación de rapamicina por FDA
![Page 47: De la EPOC al Cancer de Pulmón](https://reader033.vdocumento.com/reader033/viewer/2022052313/5887ab0a1a28aba2088b68ad/html5/thumbnails/47.jpg)
1940 1950 1960 1970 1980 1990 2000 20101930
1950: asociación entre cáncer de pulmón y tabaco
‘The risk of developing the disease increases in proportion to the
amount smoked. It may be 50 times as great among those who smoke
25 or more cigarettes a day asamong non-smokers.’
Doll R, et al. Br Med J 1950
![Page 48: De la EPOC al Cancer de Pulmón](https://reader033.vdocumento.com/reader033/viewer/2022052313/5887ab0a1a28aba2088b68ad/html5/thumbnails/48.jpg)
Anthonisen NR. The effects of a smoking cessation intervention on 14.5-year mortality. Ann Intern Med 2005
Mortality rates at 14.5 years by cause and smoking status